Brock Biology Of Microorganism

Brock Biology Of Microorganisms

Title: Brock biology of microorganisms, 14th edition

Author- Thomas Brock

Edition: 14

Publisher: Pearson

ISBN-10:  0321897390

Length- 1136 pages

Language - English

Diagnostic Microbiology

Diagnostic Microbiology

Title - Bailey & Scott's Diagnostic Microbiology - E-Book

Author  Patricia Tille

Description- Hands-on procedures include step-by-step instructions, full-color photos, and expected results, helping you achieve more accurate results.Case studies give you the opportunity to apply your skills in a variety of diagnostic scenarios and help improve your decision-making and critical thinking skills.Genera and Species to be Considered boxes highlight all of the organisms to be discussed each chapter, including the current name of the species as well as any previous names.Student resources on Evolve enhance your learning with review questions and procedures.Convenient, easy-to-read tables summarize key information.Detailed, full-color illustrations aid comprehension and help you visualize concepts.A glossary of terms is found at the back of the book for quick reference.

Edition-13

Publisher -Elsevier Health Sciences, 2013

ISBN-032327742X, 9780323277426

Length-1056 pages

Subjects -Medical › Allied Health Services 

Goodnight Pharm

Goodnight Pharm

Title       Goodnight Pharm: 350 Brand and Generic Drug Names with Classifications

Author  Tony Guerra

Edition - illustrated

Publisher- Lulu.com, 2017

ISBN- 1387018116, 9781387018116

Length  - 252 pages

Subjects- Science › General

Nefopam & Nemuslide

Nefopam & Nemuslide

The mechanism of action of nefopam and its analgesic effects are not well understood, although inhibition of the reuptake of serotonin, nor epinephrine, and to a lesser extent dopamine (that is, acting as an SNDRI is thought to be involved. It also reduces glutamate signaling via modulating sodium and calcium channels

Nimesulide is a prescription non-steroidal anti-inflammatory drug with a multifactorial mode of action, characterized by a fast onset of analgesic activity. This NSAID is a weak inhibitor of PG synthesis and moderately COX-2 Selective. Anti-inflammatory action may be exerted by other mechanisms as well, e.g. reduced generation of superoxide by neutrophils, inhibition of PAF synthesis and TNFa release, free scavenging, inhibition of metalloproteinase activity in cartilage.

Reference

Tripathi K.D.,” Essentials of Medical Pharmacology”, Jaypee Brothers Medical Publishers (P) LTD, New Delhi, Seventh Edition, Pg No. 207, 208

Naltrexone

Naltrexone

The blockade of opioid receptors is the basis behind naltrexone's action in the management of opioid dependence—it reversibly blocks or attenuates the effects of opioids. Its mechanism of action in alcohol dependence is not fully understood, but as an opioid receptor antagonist is likely to be due to the modulation of the dopaminergic mesolimbic pathway (one of the primary centers for risk-reward analysis in the brain, and a tertiary "pleasure center") which is hypothesized to be a major center of the reward associated with addiction that all major drugs of abuse are believed to activate. Mechanism of action may be antagonism to endogenous opioids such as tetrahydropapaveroline, whose production is augmented in the presence of alcohol.

Reference

Tripathi K.D.,” Essentials of Medical Pharmacology”, Jaypee Brothers Medical Publishers (P) LTD, New Delhi, Seventh Edition, Pg No. 483-84

Nadifloxacin

Nadifloxacin

Nadifloxacin inhibits the enzyme DNA gyrase that is involved in bacterial DNA synthesis and replication, thus inhibiting the bacterial multiplication. Nadifloxacin in addition to determine a therapeutic antibacterial action, can have a sebostatic and anti-inflammatory action, thus contributing to the improvement of the clinical condition of the patient

Reference

Tripathi K.D.,” Essentials of Medical Pharmacology”, Jaypee Brothers Medical Publishers (P) LTD,New Delhi, Seventh Edition, Pg No. 894

Nilotinib

 NILOTINIB

Nilotinib is a transduction inhibitor that targets BCR-ABL, c-kit and PDGF, for the potential treatment of various leukemias, including chronic myeloid leukemia (CML). Chronic myelogenous leukemia (CML) is caused by the BCR-ABL oncogene. Nilotinib inhibits the tyrosine kinase activity of the BCR-ABL protein.

Nilotinib 

Reference

Tripathi K.D.,” Essentials of Medical Pharmacology”, Jaypee Brothers Medical Publishers (P) LTD, New Delhi, Seventh Edition, Pg No. 870